文献速递心血管技术与安全US

骨髓间充质干细胞预处理可增强超声靶向微泡破坏介导的局部联合基因治疗对心肌梗死后心力衰竭大鼠的治疗效果

Pre-transplantation of Bone Marrow Mesenchymal Stem Cells Amplifies the Therapeutic Effect of Ultrasound-Targeted Microbubble Destruction-Mediated Localized Combined Gene Therapy in Post-Myocardial Infarction Heart Failure Rats.
PubMed 文献 · Ultrasound Med Biol · 2022-03-01

在大鼠慢性心肌梗死模型中,先向梗死区及边缘区注射骨髓间充质干细胞(BMSCs),4周后经超声靶向微泡破坏(UTMD)递送SERCA2a与Cx43双基因;同时过表达SERCA2a和Cx43的大鼠收缩功能与电稳定性最佳,且BMSCs预处理组在基因转染后机械-电功能优于未移植BMSCs组。

要点

  • UTMD可经静脉递送SERCA2a与Cx43双基因至梗死心肌,双基因过表达组收缩功能与电稳定性最佳。
  • BMSCs预处理4周后再行双基因UTMD,大鼠机械-电功能优于未移植BMSCs者。
  • 免疫荧光显示SERCA2a和/或Cx43蛋白水平显著升高,尤以梗死边缘区明显。

核心结论

  • 联合BMSCs预处理与UTMD介导的SERCA2a和Cx43局部共递送,可增强心肌梗死后心脏修复,同时过表达SERCA2a和Cx43的大鼠收缩功能与电稳定性最佳。

研究设计与样本

  • 大鼠心肌梗死模型研究:结扎左前降支并向右心室梗死区及边缘区注射BMSCs,4周后经UTMD递送SERCA2a与Cx43基因,4周后检测心脏机械-电功能、梗死面积及SERCA2a、Cx43和心肌特异性标志物表达。

关键影像表现/征象

  • 自组装基因负载微泡为微米级,双基因负载能力满意且基因负载率合格。
  • 体外超声辐照下实现高转染效率。
  • 免疫荧光显示SERCA2a和/或Cx43蛋白水平显著升高,尤以梗死边缘区明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Although stem cell transplantation and single-gene therapy have been intensively discussed separately as treatments for myocardial infarction (MI) hearts and have exhibited ideal therapeutic efficiency in animal models, clinical trials turned out to be disappointing. Here, we deliver sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) and connexin 43 (Cx43) genes simultaneously via an ultrasound-targeted microbubble destruction (UTMD) approach to chronic MI hearts that have been pre-treated with bone marrow mesenchymal stem cells (BMSCs) to amplify cardiac repair. First, biotinylated microbubbles (BMBs) were fabricated, and biotinylated recombinant adenoviruses carrying the SERCA2a or Cx43 gene were conjugated to the surface of self-assembled BMBs to form SERCA2a-BMBs, Cx43-BMBs or dual gene-loaded BMBs. Then, the general characteristics of these bubbles, including particle size, concentration, contrast signal and gene loading capacity, were examined. Second, a rat myocardial infarction model was created by ligating the left anterior descending coronary artery and injecting BMSCs into the infarct and border zones. Four weeks later, co-delivery of SERCA2a and Cx43 genes to the infarcted heart were delivered together to the infarcted heart using the UTMD approach. Cardiac mechano-electrical function was determined 4 wk after gene transfection, and the infarcted hearts were collected for myocardial infarct size measurement and detection of expression of SERCA2a, Cx43 and cardiac-specific markers. Finally, to validate the role of BMSC transplantation, MI rats transplanted or not with BMSCs were transfected with SERCA2a and Cx43, and the cardiac mechano-electrical function of these two groups of rats was recorded and compared. General characteristics of the self-assembled gene-loaded BMBs were qualified, and the gene loading rate was satisfactory. The self-assembled gene-loaded BMBs were in microscale and exhibit satisfactory dual-gene loading capacity. High transfection efficiency was achieved under ultrasound irradiation in vitro. In addition, rats in which SERCA2a and Cx43 were overexpressed simultaneously had the best contractile function and electrical stability among all experimental groups. Immunofluorescence assay revealed that the levels of SERCA2a and/or Cx43 proteins were significantly elevated, especially in the border zone. Moreover, compared with rats that did not receive BMSCs, rats pre-treated with BMSCs have better mechano-electrical function after transfection with SERCA2a and Cx43. Collectively, we report a promising cardiac repair strategy for post-MI hearts that exploits the providential advantages of stem cell therapy and UTMD-mediated localized co-delivery of specific genes.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Wang, Tayier, Guan, et al. Pre-transplantation of Bone Marrow Mesenchymal Stem Cells Amplifies the Therapeutic Effect of Ultrasound-Targeted Microbubble Destruction-Mediated Localized Combined Gene Therapy in Post-Myocardial Infarction Heart Failure Rats. Ultrasound Med Biol. 2022. PMID: 35246339. doi:10.1016/j.ultrasmedbio.2022.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。